PFF Launches Drug Development Pipeline Tool
The Pulmonary Fibrosis Foundation (PFF) launched a new PF Drug Development Pipeline tool to help the pulmonary fibrosis (PF) community search for different treatment options currently in development for interstitial lung diseases.
Building off PFF’s Clinical Trials Education Center, the Pipeline tool features news about recent drug and study announcements, as well as links to relevant trials on the Clinical Trial Finder page to ensure patients are aware of opportunities to participate in clinical trials targeted at their specific conditions. The tool allows viewers to filter search results by study phase, disease/condition, intervention type and more.
In addition, users can access a Drug Development Pipeline Glossary to better understand the development process, and a user feedback form to share any questions or concerns they have with the tool to aid in future enhancements.
In addition, the PFF connects PF researchers to valuable medical information from more than 2,000 patient volunteers through the PFF Patient Registry. This research tool offers a combination of data from a wide range of patients, including those with less-studied forms of PF, to generate a resource for future research into treatments and provides data for improving and reassessing existing care guidelines.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
